Release
📈 Stocks
Eloxx Pharmaceuticals Publishes Phase 2a Exaluren Data for Alport Syndrome
(just now)
Eloxx Pharmaceuticals reports positive Phase 2a proof-of-mechanism data for exaluren in Alport syndrome, showing improved kidney cell structure in three patients, with…